% Free PSA: Which Tests to Order Alongside for a Complete Prostate Workup

What % Free PSA Actually Measures

Prostate-specific antigen circulates in two forms: bound to proteins (complexed PSA) and unbound (free PSA). The % Free PSA is the ratio of free PSA to total PSA, multiplied by 100. Prostate cancer cells tend to release PSA that binds more readily to serum proteins, which pushes the free fraction down.

A man with a total PSA of 7 ng/mL and a free PSA of 0.7 ng/mL has a % Free PSA of 10%. That same total PSA with a free PSA of 1.75 ng/mL yields 25%. The clinical difference is substantial. In the landmark Catalona et al. study of 773 men with total PSA between 4 and 10 ng/mL, a % Free PSA cutoff of 25% detected 95% of cancers while potentially avoiding 20% of unnecessary biopsies 1. The test does not diagnose cancer. It refines probability. And probability improves further when you add the right companion labs.

The National Comprehensive Cancer Network (NCCN) Early Detection Guidelines (Version 1.2024) list % Free PSA as one of several "secondary biomarkers" that should be considered before proceeding to biopsy when total PSA is in the 3-10 ng/mL range 2. The guideline explicitly states: "Clinicians should consider additional testing (percent free PSA, PHI, 4Kscore, SelectMDx, ExoDx, or mpMRI) prior to biopsy."

The First Paired Test: Total PSA (and Why Timing Matters)

% Free PSA requires a same-draw total PSA to calculate the ratio. This sounds obvious, but ordering them on separate days introduces assay variability that can shift the percentage by several points. Both must come from the same blood sample.

Total PSA itself fluctuates. Ejaculation within 24-48 hours, vigorous cycling, urinary tract infections, prostatitis, and recent digital rectal exam can all transiently raise total PSA 3. The AUA recommends that any elevated PSA be confirmed with a repeat draw at 6-8 weeks before pursuing invasive workup 4. A single elevated total PSA paired with a low % Free PSA does not, by itself, mandate biopsy.

Age-specific PSA reference ranges also matter. A total PSA of 5.5 ng/mL in a 75-year-old man carries a different pretest probability than the same value in a 48-year-old. The Oesterling et al. data established age-specific ranges: 0-2.5 ng/mL for men 40-49, 0-3.5 for 50-59, 0-4.5 for 60-69, and 0-6.5 for 70-79 5. When a man's total PSA is within his age-appropriate range, a borderline % Free PSA becomes less concerning.

Prostate Health Index (PHI): The Strongest Companion Biomarker

The Prostate Health Index combines three PSA isoforms into a single score: total PSA, free PSA, and [-2]proPSA (p2PSA). The formula is (p2PSA / free PSA) × √total PSA. PHI outperforms % Free PSA alone for distinguishing clinically significant prostate cancer (Gleason ≥ 7) from indolent disease.

In the prospective multicenter trial by Loeb et al. (N=658 men with PSA 4-10 ng/mL), PHI at a cutoff of 28.6 showed an AUC of 0.72 for detecting Gleason ≥ 7 cancer, compared to 0.67 for % Free PSA alone 6. That difference translates to roughly 30% fewer unnecessary biopsies without missing aggressive tumors.

PHI requires ordering three specific assays from the same blood draw: total PSA, free PSA, and p2PSA. The [-2]proPSA is not universally available at all reference labs, so confirm your lab offers the Beckman Coulter Access platform or equivalent before ordering. The FDA cleared PHI in 2012 specifically for men aged 50 and older with total PSA between 4 and 10 ng/mL and a non-suspicious digital rectal exam 7.

Dr. Stacy Loeb, urologic oncologist at NYU Langone, has written: "PHI should be the preferred first-line reflex test in men with PSA 4-10 ng/mL because it incorporates the information from % Free PSA while adding the discriminatory power of p2PSA, a more cancer-specific isoform" 6.

4Kscore: A Blood-Based Multivariate Panel

The 4Kscore test measures four kallikrein markers (total PSA, free PSA, intact PSA, and human kallikrein 2) and integrates them with clinical variables (age, DRE result, prior biopsy status) through a validated algorithm. It outputs a percentage probability of finding Gleason ≥ 7 cancer on biopsy.

The European Randomized Study of Screening for Prostate Cancer (ERSPC) validation cohort showed the 4Kscore had an AUC of 0.82 for high-grade cancer detection 8. In a U.S. validation study of 1,012 men scheduled for biopsy, using a 4Kscore threshold of 7.5% would have avoided 49% of biopsies while missing only 4.7% of high-grade cancers 8.

The 4Kscore is a send-out test processed by OPKO Lab. It requires a standard serum sample (same draw as your PSA panel) plus a clinical questionnaire completed by the ordering provider. Results typically return in 2-3 business days.

When should you choose 4Kscore over PHI? If the patient has had a prior negative biopsy and PSA remains elevated, the 4Kscore's integration of prior biopsy status gives it an edge. For biopsy-naive men, either test adds value over % Free PSA alone.

PSA Density and Prostate Volume

PSA density (PSAD) divides total PSA by prostate volume in cubic centimeters, measured by transrectal ultrasound (TRUS) or MRI. A gland that weighs 80 grams produces more PSA simply because there is more tissue. PSAD corrects for this.

The NCCN uses a PSAD cutoff of ≥ 0.15 ng/mL/cc as one factor supporting biopsy consideration 2. A man with total PSA of 6.0 ng/mL and a 60-cc prostate has a PSAD of 0.10, which is reassuring. The same PSA with a 30-cc prostate yields 0.20, which warrants closer evaluation.

PSAD requires imaging, so it is not a blood test you can simply add to a lab requisition. But if your patient already has a pelvic or prostate MRI (increasingly common with the adoption of mpMRI before biopsy), prostate volume is reported on the radiology read. Pair that volume with the same-day total PSA to calculate PSAD. The PI-RADS v2.1 guidelines from the American College of Radiology recommend integrating PSAD into the decision pathway for PI-RADS 3 lesions 9.

PSA Velocity and Doubling Time

PSA velocity measures the rate of PSA change over time, expressed as ng/mL per year. PSA doubling time estimates how long it takes for PSA to double. Both require at least two (preferably three) total PSA values drawn over 18-24 months.

The AUA's 2023 Early Detection guideline notes that a PSA velocity exceeding 0.75 ng/mL per year raises concern for cancer, independent of the absolute PSA value 4. A rapidly rising PSA with a concurrently declining % Free PSA is a particularly worrisome combination.

PSA velocity is not a separate lab order. It is a calculation derived from serial total PSA values already in the chart. The clinical action step is to ensure you are trending total PSA over time, not just interpreting a single snapshot paired with % Free PSA.

Testosterone: The Underappreciated PSA Modifier

Testosterone directly influences PSA production. Hypogonadal men (total testosterone <300 ng/dL) may have artificially low PSA levels that mask underlying pathology. Conversely, men initiating testosterone replacement therapy (TRT) often see PSA rise by 0.5-1.0 ng/mL in the first 6-12 months, a pharmacologic effect rather than a sign of cancer 10.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy recommends checking PSA at baseline, at 3-6 months after starting TRT, and then annually 11. Dr. Shalender Bhasin, lead author of the guideline, stated: "A PSA increase of more than 1.4 ng/mL within any 12-month period on testosterone therapy should prompt urological evaluation, regardless of the absolute PSA value."

For men on TRT whose PSA enters the gray zone, % Free PSA paired with PHI provides critical context. A rising total PSA with a stable or increasing % Free PSA (above 25%) is far more consistent with BPH stimulation from testosterone than with occult malignancy.

Ordering a concurrent total testosterone and sex hormone-binding globulin (SHBG) alongside your PSA panel costs little and can prevent a cascade of unnecessary anxiety and procedures. Free testosterone, calculated from total testosterone and SHBG, is the fraction that drives prostatic tissue growth and PSA secretion.

Metabolic and Inflammatory Markers Worth Adding

Chronic inflammation and metabolic dysfunction both influence PSA levels. A complete metabolic panel (CMP), C-reactive protein (CRP), and hemoglobin A1c can provide context for borderline PSA results.

Obesity is associated with lower PSA concentrations through hemodilution (larger plasma volume dilutes the analyte), which may cause false reassurance. In the Prostate Cancer Prevention Trial (PCPT, N=5,058 placebo-arm men who underwent end-of-study biopsy), obese men (BMI ≥ 30) had 11.4% lower mean PSA levels than men with normal BMI, despite having similar cancer detection rates on biopsy 12. A low-normal total PSA in an obese man may warrant more careful scrutiny than the same value in a lean man.

Prostatitis, whether bacterial or chronic pelvic pain syndrome, elevates total PSA and can depress % Free PSA, mimicking a cancer-like pattern. If CRP is elevated or the patient reports dysuria, pelvic pain, or recent UTI, repeat the PSA panel after treatment. A urinalysis with culture should accompany any PSA workup in a symptomatic man.

Building the Optimal Lab Panel: A Practical Ordering Guide

For a man presenting with total PSA in the 3-10 ng/mL range and no prior biopsy, the evidence supports this paired testing approach.

Minimum panel (same blood draw):

• Total PSA
• Free PSA (to calculate % Free PSA)
• Complete metabolic panel
• Total testosterone

Enhanced panel (when available):

• All of the above, plus [-2]proPSA (to calculate PHI)
• Or 4Kscore panel (if prior negative biopsy)

Add if clinically indicated:

• SHBG and calculated free testosterone (men on TRT or suspected hypogonadism)
• CRP and urinalysis (if infection or inflammation is suspected)
• CBC (to establish baseline hemoglobin, especially if TRT is under consideration)

Imaging-derived (not blood tests, but essential companions):

• Prostate volume for PSAD calculation (from TRUS or mpMRI)
• mpMRI with PI-RADS scoring before biopsy (NCCN Category 2A recommendation)

Timing matters. Draw the panel in the morning, fasting if CMP and lipids are included. The patient should avoid ejaculation for 48 hours prior and should not have undergone DRE, cystoscopy, or prostate biopsy within the preceding 6 weeks. If the initial panel shows elevated total PSA with low % Free PSA but no other red flags, repeat the full panel at 6-8 weeks before escalating to imaging or biopsy referral.

How to Interpret % Free PSA in Context

The percentage alone is a probability modifier, not a binary answer. A 2004 meta-analysis by Lee et al. pooled data from 18 studies (N=6,630 men) and found the following cancer detection rates by % Free PSA range in men with total PSA 4-10 ng/mL 13:

• % Free PSA 0-10%: 56% cancer on biopsy
• % Free PSA 10-15%: 28% cancer on biopsy
• % Free PSA 15-20%: 20% cancer on biopsy
• % Free PSA 20-25%: 16% cancer on biopsy
• % Free PSA >25%: 8% cancer on biopsy

These probabilities shift when you layer in PHI, 4Kscore, PSAD, and clinical variables. A man with % Free PSA of 18%, PHI of 24, PSAD of 0.09, and a normal DRE has a very different risk profile from a man with the same % Free PSA but a PHI of 45, PSAD of 0.22, and a palpable nodule.

No single biomarker replaces clinical judgment. The value of paired testing is that it converts a vague "maybe" into a quantified probability that patients and clinicians can use to make shared decisions about whether to biopsy, image, or monitor.

How to Lower or Raise % Free PSA

This question comes up frequently, but it reflects a misunderstanding of what the test measures. You do not want to manipulate % Free PSA. You want to ensure that the result accurately reflects your prostate biology.

5-alpha reductase inhibitors (finasteride 5 mg, dutasteride 0.5 mg) roughly halve total PSA after 6 months of use but do not meaningfully change the % Free PSA ratio 14. If a man takes finasteride for BPH, his total PSA should be doubled for screening interpretation, but his % Free PSA remains interpretable at face value.

Ejaculation within 48 hours before the draw can transiently raise total PSA while shifting the free-to-total ratio. Acute prostatitis drives total PSA up dramatically and compresses % Free PSA. Proper specimen timing (no ejaculation for 48 hours, no active urinary symptoms, morning fasting draw) produces the most reliable result.

There is no supplement, diet, or medication that selectively raises or lowers % Free PSA in a clinically meaningful way without also changing total PSA. If someone is searching for ways to change this number, what they really need is a properly timed, properly paired lab panel and a clinician who can interpret the full picture.